



## PHARMACY POLICY STATEMENT

### North Carolina Marketplace

DRUG NAME	Aubagio (teriflunomide)
BILLING CODE	Must use valid NDC
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
STATUS	Prior Authorization Required

Aubagio



DATE	ACTION/DESCRIPTION
06/12/2017	New policy for Aubagio created. Not covered diagnosis added.
12/06/2017	Age coverage expanded. Confirmation of diagnosis based on McDonald criteria is no longer required.
07/19/2022	Transferred to new template. Updated and added references. Made correction to move CIS from exclusion to indication. Added LFT monitoring and TB test. Added concomitant leflunomide exclusion. Created renewal criteria.

References:

1. Aubagio [package insert]. Cambridge, MA; Genzyme, Inc. 2021.
2. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med*. 2011;365(14):1293-1303. doi:10.1056/NEJMoa1014656
3. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology [published correction appears in *Neurology*. 2019 Jan 8;92(2):112]. *Neurology*. 2018;90(17):777-788
4. National Multiple Sclerosis Society. The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence. A Consensus Paper by the Multiple Sclerosis Coalition; 2019. Available from: [https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT\\_Consensus\\_MS\\_Coalition.pdf](https://www.nationalmssociety.org/NationalMSSociety/media/MSNationalFiles/Brochures/DMT_Consensus_MS_Coalition.pdf). Accessed August 18, 2021.
5. He D, Zhang C, Zhao X, et al. Teriflunomide for multiple sclerosis. *Cochrane Database Syst Rev*. 2016;3:CD009882. Published 2016 Mar 22. doi:10.1002/14651858.CD009882.pub3
6. Zhang Y, Yin H, Zhang D, Xu Y, Peng B, Cui L. Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study [published online ahead of print, 2022 Apr 11]. *J Neurol*. 2022;1-9. doi:10.1007/s00415-022-11118-7
7. Papp V, Buron MD, Siersma V, et al. Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis Registry. *PLoS One*. 2021;16(5):e0250820. Published 2021 May 18. doi:10.1371/journal.pone.0250820

Effective date: 01/01/2023

Revised date: 07/19/2022